Baktiar Hasan

Combined Military Hospital — Pakistan

Medicine · Health Sciences

25h-index3.0kcitations63works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(29), Lung Cancer Diagnosis and Treatment(16), Lung Cancer Research Studies(16), Lymphoma Diagnosis and Treatment(7), Cutaneous lymphoproliferative disorders research(7)

Publications63 total

<b>TO FIND OUT THE ETIOLOGY OF LOWER GASTROINTESTINAL TRACT BLEEDING IN PEDIATRIC PATIENTS PRESENTING TO A TERTIARY CARE HOSPITAL</b>
Journal of medical & health sciences review.·2025Open Access
Immunohistochemical expression of smoothened in periocular basal cell, squamous cell and sebaceous carcinomas
Scientific Reports·2025Open Access
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
Lung Cancer·2021· 9 cited
LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
Annals of Oncology·2020· 25 citedOpen Access
1919P Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)
Annals of Oncology·2020· 1 citedOpen Access
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
Journal of Thoracic Oncology·2020· 49 citedOpen Access
EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease
European Journal of Cancer·2019· 44 citedOpen Access
Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion
European Journal of Cancer·2019· 26 citedOpen Access
Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey
Lung Cancer·2019· 26 citedOpen Access
Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report
Journal of Thoracic Oncology·2019· 281 citedOpen Access
Sample size computation in phase II designs combining the A’Hern design and the Sargent and Goldberg design
Journal of Biopharmaceutical Statistics·2019· 3 cited
Defining Synchronous Oligometastatic Non–Small Cell Lung Cancer: A Systematic Review
Journal of Thoracic Oncology·2019· 70 citedOpen Access
MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts
Journal of Thoracic Oncology·2018· 6 cited
P2.06-36 EORTC 1205: Randomized Phase II Study of Pleurectomy/Decortication Preceded or Followed by Chemotherapy in Early Stage MPM
Journal of Thoracic Oncology·2018
MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC
Journal of Thoracic Oncology·2018· 4 citedOpen Access
MA25.03 Defining Oligometastatic Non-Small Cell Lung Cancer (NSCLC): An Evolving Multidisciplinary Expert Opinion
Journal of Thoracic Oncology·2018· 5 citedOpen Access
A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial
Annals of Oncology·2018· 9 citedOpen Access
A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.
Journal of Clinical Oncology·2018· 9 cited
182P Real world anti-PD-L1 treatment (tx) outcomes in a multinational European non-small cell lung cancer (NSCLC) cohort with focus on toxicity (tox) and brain metastases (BM): Preliminary data from an EORTC young investigators lung cancer group collaborative analysis
Journal of Thoracic Oncology·2018Open Access
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer
The Pharmacogenomics Journal·2018· 6 cited
page 1 of 4Next →

Frequent Co-authors

Mary O’Brien(19), Benjamin Besse(16), Anne‐Marie C. Dingemans(13), Thierry Berghmans(12), Silvia Novello(11), Paul Baas(11), Jessica Menis(11), Lizza Hendriks(10), Antonin Lévy(10), Jan P. van Meerbeeck(9), Laurent Greillier(8), Lesley Seymour(8), Corinne Faivre‐Finn(7), Matteo Giaj Levra(7), Niccolò Giaj‐Levra(7), Rabab Gaafar(7), Keyue Ding(6), Frances A. Shepherd(6), Veerle Surmont(6), Urania Dafni(6)